Meliacinol



Compound IDCDAMM01814
Common nameMeliacinol
IUPAC name[6-(furan-3-yl)-12,17-dihydroxy-1,5,11,16-tetramethyl-8-oxo-7,14-dioxapentacyclo[11.6.1.02,11.05,10.016,20]icos-9-en-19-yl] 2,3-dimethylbut-2-enoate
Molecular formulaC32H42O8

Experimental data

Retention time3.48
Adduct[M+H]+
Actual mz555.293
Theoretical mz555.295
Error3.38
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.7522

Identifiers and class information

Inchi keyJAOOSUNNEZDAPO-ZKDFNWMRNA-N
SmilesO=C1OC(C2=COC=C2)C3(C(=C1)C4(C)C(O)C5OCC6(C)C(O)CC(OC(=O)C(=C(C)C)C)C(C)(C4CC3)C56)C
SuperclassOrganoheterocyclic compounds
ClassNaphthopyrans

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)4
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)554.679
Computed dipole moment(dipole)11.398
Total solvent accessible surface area (SASA)740.921
Hydrophobic component of SASA (FOSA)454.225
Hydrophilic component of SASA (FISA)157.812
Pie component of the SASA (PISA)128.884
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1544.15
Number of hydrogen bond donors (donorHB)2
Number of hydrogen bond acceptors (accptHB)10.6
Free energy of solvation of dipole (dip^2/V)0.0841359
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0202325
Globularity descriptor (glob)0.872004
Predicted polarizability in cubic angstroms (QPpolrz)54.305
Predicted hexadecane/gas partition coefficient (QPlogPC16)14.79
Predicted octanol/gas partition coefficient (QPlogPoct)28.297
Predicted water/gas partition coefficient (QPlogPw)15.94
Predicted octanol/water partition coefficient (QPlogPo/w)3.563
Predicted aqueous solubility (QPlogS)-5.276
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.714
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.218
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)315.77
Predicted brain/blood partition coefficient (QPlogBB)-1.061
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)142.308
Predicted skin permeability, log Kp (QPlogKp)-3.59
PM3 calculated ionization potential (IP(ev))9.499
PM3 calculated electron affinity (EA(eV))0.55
Number of likely metabolic reactions (#metab)8
Prediction of binding to human serum albumin (QPlogKhsa)0.603
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)79.585
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)120.705
Number of nitrogen and oxygen atoms (#NandO)8
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P35372OPRM1Mu opioid receptorT47768SEA
P41145OPRK1Kappa Opioid receptorT60693SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T47768DI0013Acute pain[ICD-11: MG31]P35372OPRM1
T47768DI0059Bowel habit change[ICD-11: ME05]P35372OPRM1
T47768DI0087Chronic pain[ICD-11: MG30]P35372OPRM1
T47768DI0101Corneal disease[ICD-11: 9A76-9A78]P35372OPRM1
T47768DI0105Cough[ICD-11: MD12]P35372OPRM1
T47768DI0117Depression[ICD-11: 6A70-6A7Z]P35372OPRM1
T47768DI0124Digestive system disease[ICD-11: DE2Z]P35372OPRM1
T47768DI0218Irritable bowel syndrome[ICD-11: DD91]P35372OPRM1
T47768DI0228Large intestine motility disorder[ICD-11: DB32]P35372OPRM1
T47768DI0317Opioid use disorder[ICD-11: 6C43]P35372OPRM1
T47768DI0324Pain[ICD-11: MG30-MG3Z]P35372OPRM1
T47768DI0349Pruritus[ICD-11: EC90]P35372OPRM1
T47768DI0374Sensation disturbance[ICD-11: MB40]P35372OPRM1
T60693DI0304Non-specific cutaneous vascular symptom[ICD-11: ME64]P41145OPRK1
T60693DI0324Pain[ICD-11: MG30-MG3Z]P41145OPRK1
T60693DI0349Pruritus[ICD-11: EC90]P41145OPRK1

Copyright © 2025